Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Amgen Inc.
IndexS&P 500 P/E25.30 EPS (ttm)6.35 Insider Own0.10% Shs Outstand760.67M Perf Week-1.72%
Market Cap122.22B Forward P/E17.22 EPS next Y9.33 Insider Trans4.25% Shs Float759.86M Perf Month-2.14%
Income4.89B PEG2.27 EPS next Q2.05 Inst Own82.90% Short Float1.12% Perf Quarter15.32%
Sales19.74B P/S6.19 EPS this Y20.30% Inst Trans1.58% Short Ratio2.04 Perf Half Y36.02%
Book/sh33.28 P/B4.83 EPS next Y8.36% ROA7.10% Target Price168.81 Perf Year45.90%
Cash/sh36.91 P/C4.35 EPS next 5Y11.14% ROE20.70% 52W Range106.69 - 173.14 Perf YTD43.57%
Dividend2.44 P/FCF22.90 EPS past 5Y12.00% ROI10.50% 52W High-7.20% Beta0.51
Dividend %1.52% Quick Ratio3.90 Sales past 5Y4.50% Gross Margin80.40% 52W Low50.60% ATR4.92
Employees20000 Current Ratio4.20 Sales Q/Q6.00% Oper. Margin34.90% RSI (14)47.77 Volatility3.86% 2.74%
OptionableYes Debt/Eq1.30 EPS Q/Q-10.10% Profit Margin24.70% Rel Volume0.53 Prev Close157.52
ShortableYes LT Debt/Eq1.20 EarningsJan 26 AMC Payout35.70% Avg Volume4.17M Price160.67
Recom2.30 SMA20-2.98% SMA501.47% SMA20021.84% Volume2,222,853 Change2.00%
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
Sep-12-12Downgrade Robert W. Baird Outperform → Neutral $84
Sep-10-12Upgrade UBS Neutral → Buy $80 → $96
Dec-24-14 06:24PM  Biotech Stocks Take A Beating, But Find Support at Investor's Business Daily
04:56PM  Top U.S. Stock Mutual Funds Of 2014: How They Did It at Investor's Business Daily
01:01PM  Are There Any Winners Left In The Biotech Space? Benzinga
Dec-23-14 05:48PM  Buy biotech dip? CNBC
Dec-22-14 09:15AM  Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts PR Newswire
Dec-17-14 05:45PM  Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend PR Newswire
03:11PM  Leaked Sony emails show Loeb influence on studio execs Reuters
01:05PM  Is a Biosimilar (Generic) Top Cancer Drug for You? at 24/7 Wall St.
01:04PM  Amgen Leukemia Treatment to Cost $178,000, Among Priciest Drugs at Bloomberg
12:59PM  Midday Movers: Carnival, Chevron, Netflix & more at CNBC
Dec-15-14 04:44PM  Where is Santa rally? Yahoo Finance Blogs
10:04AM  Is This The Future Of Late-Stage Drug Development? at Forbes
09:34AM  Biotech Entrepreneur Tony Coles Takes Aim At Parkinson's And Alzheimer's at Forbes
Dec-13-14 08:02AM  Meet 5 Top Biotech Stocks Holding Up In Shaky Market at Investor's Business Daily
Dec-11-14 05:38PM  How Can Drugmakers Handle New Pricing Pressures? at Investor's Business Daily
04:01PM  Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1 Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire
03:45PM  bluebird bio (BLUE) Soars on Data from LentiGlobin Study Zacks
06:00AM  How Amgen Makes Billions On Just A Few Drugs at Investopedia
Dec-10-14 05:15PM  Equity markets felland fell hard (no recovery like yesterday) Yahoo Finance Blogs
02:10PM  Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data Zacks
08:16AM  The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan Zacks
Dec-09-14 05:20PM  Dynavax & AstraZeneca Alter Agreement for Asthma Product Zacks
04:00PM  Amgen Successfully Expands Xgeva Label in the U.S. Zacks
08:02AM  Big-Cap Stock Funds Tend To Lag at Investor's Business Daily
Dec-08-14 09:00PM  Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia PR Newswire
06:05PM  Amgen Unveils Positive Results from Blood Cancer Studies Zacks
05:50PM  Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks
04:20PM  New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma PR Newswire
02:17PM  Federal Appeals Court Declines to Address a Crucial Biosimilar Question at The Wall Street Journal
01:12PM  Midday movers: McDonald's, Sony, Celgene & more at CNBC
12:37PM  Celgene CEO: Cancer drug pipeline booming CNBC
11:21AM  Amgen's bone drug Xgeva gets new approval AP
09:00AM  FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy PR Newswire
03:53AM  Novartis copy of Amgen biotech drug shows similar efficacy-study Reuters
Dec-06-14 01:00PM  Amgen Announces New Data From Phase 2 BLINCYTO (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease PR Newswire
11:00AM  Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting at TheStreet
11:00AM  Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma PR Newswire
11:00AM  Addition of Amgen drug boosts benefits in relapsed myeloma -study Reuters
01:55AM  Next Week at
Dec-05-14 06:10PM  Cramer's gameplan: Market party until 2015 at CNBC
06:00PM  Next week's game plan: Agios & United Tech CNBC
02:09PM  Sandoz loses bid to shield psoriasis drug Reuters
09:20AM  Bayer Files Hemophilia A Drug Marketing Application in EU Zacks
Dec-04-14 05:45PM  Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning Zacks
Dec-03-14 07:00PM  Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition PR Newswire
06:14PM  Amgen gets approval for novel leukemia drug AP
04:30PM  Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts Website And Resources PR Newswire
03:48PM  FDA Approves BLINCYTO (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
01:45PM  U.S. FDA approves Amgen leukemia drug ahead of schedule Reuters
01:31PM  Amgen Wins U.S. Approval for Immunotherapy Against Leukemia at TheStreet
11:57AM  Biotech: When and Where to Sell at Forbes
Dec-02-14 05:34PM  A Look At 3 Overbought ETFs Benzinga
05:05PM  Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU Zacks
04:41PM  Today's Glance at the Market... Yahoo Finance Blogs
01:49PM  Big CEOs Are Less Upbeat, But Plan To Hire More at Investor's Business Daily
09:00AM  Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment Marketwired
08:02AM  Meet 5 Top Drug Stocks That Are Bolting Past Market at Investor's Business Daily
Dec-01-14 03:51PM  Apple down, Nasdaq down CNBC
Nov-28-14 04:00PM  Alexion's Soliris Gets Final Positive NICE Recommendation Zacks
08:34AM  The Zacks Analyst Blog Highlights: BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex Zacks
Nov-26-14 04:30PM  AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study Zacks
09:54AM  Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Zacks
Nov-25-14 04:01PM  Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire
09:35AM  Tiffany sparkles; Campbell Soup on the move; Sony's new plan Hot Stock Minute
07:13AM  Stock stumble after consumer confidence slips; GDP data revised up; Elsa and Disney overtake Barbie Hot Stock Minute
05:00AM  More Medicine Goes Off Limits in Drug-Price Showdown at Bloomberg
Nov-24-14 04:57PM  After-hours buzz: Amgen, Palo Alto Networks & more at CNBC
01:28PM  Amgen ends studies of gastric cancer drug AP
12:00PM  JANA Partners opens a stake in Amgen Market Realist
10:35AM  Amgen Ends Trials of Stomach-Cancer Therapy at The Wall Street Journal
10:23AM  Amgen Surprise, Discontinues Stomach Cancer Drug Study at 24/7 Wall St.
09:57AM  Amgen ends trials of stomach-cancer therapy at MarketWatch
09:57AM  Amgen Stops Gastric-Cancer Drug Trials on Increase in Deaths at Bloomberg
09:32AM  Amgen scraps trials of drug for advanced stomach cancer Reuters
09:15AM  Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer PR Newswire
Nov-22-14 05:00AM  Motley Fool: Pundits pandering your wealth away at USA TODAY
Nov-21-14 04:00PM  Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Zacks
03:30PM  Highlights of activist fund JANA Partners 3Q 13F Market Realist
11:08AM  Loeb wins battle to appoint Dow Chemical directors at Financial Times
06:49AM  Fighting kids' cancer... fixing a broken system CNBC
Nov-20-14 08:14PM  SINGAPORE PRESS-Amgen opens S$200 mln plant in Singapore-Straits Times Reuters
Nov-19-14 10:00PM  Amgen Opens Next-generation Biomanufacturing Facility in Singapore PR Newswire
02:35PM  Will The IMPROVE-IT Results Impact The Thinking Of The FDA And Payers On LDL-Cholesterol Lowering Drugs? at Forbes
11:07AM  Stocks Boosted by Merck's Vytorin Data at
07:50AM  #PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York Benzinga
Nov-18-14 07:00PM  Amgen Inc Conference Call to Discuss Evolocumab Development Program at AHA scheduled for 7:00 pm ET today CCBN
04:00PM  Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels PR Newswire
Nov-17-14 01:41PM  Long-Awaited Study Boosts Merck, Could Be Good News for Regeneron, Amgen at
01:35PM  Merck Drug Works: Vytorin Study Proves Successful at Investor's Business Daily
12:03PM  3 Stocks Moving The Drugs Industry Upward at TheStreet
11:32AM  IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe at Forbes
Nov-15-14 07:12PM  At the American Heart Association Meeting You Really Can't Escape The New Cholesterol Drugs at Forbes
Nov-14-14 05:00PM  Biotech correction coming? 16 trades, 55 seconds CNBC
04:15PM  Amgen To Present At The Jefferies Global Healthcare Conference PR Newswire
12:15PM  Window into 13F filings CNBC
11:40AM  Jana Partners takes new stakes in Alibaba, McDonald's in 3rd qtr Reuters
Nov-13-14 06:58PM  Which Health Care ETF Should You Buy? at Investor's Business Daily
04:10PM  AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial Zacks
01:25PM  Amgen Shares Consolidating Ahead Of More Gains? Benzinga
12:06PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM